Front Immunol 2020 5;11:575258. Epub 2020 Nov 5.
Section of Hematology and Oncology, Department of Medicine, The University of Chicago, Chicago, IL, United States.
is a prognostic and predictive marker and is a validated therapeutic target in urothelial bladder cancer. Its utility as a marker and target in the context of immunotherapy is incompletely understood. We review the role of in bladder cancer and discuss preclinical and clinical clues of its effectiveness as a patient selection factor and therapeutic target in the era of immunotherapy.